Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report

Ibrutinib is an oral covalent inhibitor of the Bruton’s tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström’s macroglobulinaemia. It is generally a drug of choice for high-risk patients with i...

Full description

Saved in:
Bibliographic Details
Published inSkin appendage disorders Vol. 6; no. 1; pp. 32 - 36
Main Authors Yorulmaz, Ahu, Yalcin, Basak
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.01.2020
Subjects
Novel Insights from Clinical Practice
Paronychia
Periungual granulation
Ibrutinib
Side effect
Online AccessGet full text

Cover

More Information
Summary:Ibrutinib is an oral covalent inhibitor of the Bruton’s tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström’s macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Additionally, dermatological adverse reactions with ibrutinib therapy have been reported to encompass maculopapular rash and hair/nail abnormalities. Here, we present a case of ibrutinib-induced paronychia and periungual granulation in a 40-year-old woman. To the best of our knowledge, this is the third description of ibrutinib-induced paronychia and periungual granulation.
ISSN:2296-9195
2296-9160
DOI:10.1159/000502986